JP2025148408A5 - - Google Patents
Info
- Publication number
- JP2025148408A5 JP2025148408A5 JP2025113738A JP2025113738A JP2025148408A5 JP 2025148408 A5 JP2025148408 A5 JP 2025148408A5 JP 2025113738 A JP2025113738 A JP 2025113738A JP 2025113738 A JP2025113738 A JP 2025113738A JP 2025148408 A5 JP2025148408 A5 JP 2025148408A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- administered
- range
- enriched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025113738A JP2025148408A (ja) | 2019-10-11 | 2025-07-04 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/055770 WO2021071499A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
| JP2022522035A JP7634895B2 (ja) | 2019-10-11 | 2019-10-11 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
| JP2024000684A JP2024038270A (ja) | 2019-10-11 | 2024-01-05 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
| JP2025113738A JP2025148408A (ja) | 2019-10-11 | 2025-07-04 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000684A Division JP2024038270A (ja) | 2019-10-11 | 2024-01-05 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025148408A JP2025148408A (ja) | 2025-10-07 |
| JP2025148408A5 true JP2025148408A5 (enExample) | 2025-12-05 |
Family
ID=68387423
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522035A Active JP7634895B2 (ja) | 2019-10-11 | 2019-10-11 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
| JP2024000684A Withdrawn JP2024038270A (ja) | 2019-10-11 | 2024-01-05 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
| JP2025113738A Pending JP2025148408A (ja) | 2019-10-11 | 2025-07-04 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522035A Active JP7634895B2 (ja) | 2019-10-11 | 2019-10-11 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
| JP2024000684A Withdrawn JP2024038270A (ja) | 2019-10-11 | 2024-01-05 | パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11779597B2 (enExample) |
| EP (1) | EP4041214A1 (enExample) |
| JP (3) | JP7634895B2 (enExample) |
| AU (1) | AU2019470001B2 (enExample) |
| CA (1) | CA3154392A1 (enExample) |
| WO (1) | WO2021071499A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077524A (zh) * | 2023-02-27 | 2023-05-09 | 广西馨海药业科技有限公司 | 氯化铷在制备治疗帕金森综合征的药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2790926B2 (ja) * | 1990-08-20 | 1998-08-27 | エーザイ株式会社 | スルホンアミド誘導体 |
| ATE167473T1 (de) * | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
| US6162350A (en) | 1997-07-15 | 2000-12-19 | Exxon Research And Engineering Company | Hydroprocessing using bulk Group VIII/Group VIB catalysts (HEN-9901) |
| WO2015185602A1 (en) | 2014-06-04 | 2015-12-10 | Affiris Ag | Treatment and prevention of parkinson's disease (pd) |
| US10226484B2 (en) | 2014-12-01 | 2019-03-12 | Peter Y Novak | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
| US9861659B2 (en) | 2014-12-01 | 2018-01-09 | Vector Vitale Ip Llc | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
| KR20180105701A (ko) * | 2016-02-11 | 2018-09-28 | 모데차이 체비온 | 신경변성의 치료를 위한 방법 및 약학 조성물 |
| CN106581056A (zh) * | 2016-10-11 | 2017-04-26 | 徐志强 | 锌在制造治疗帕金森病药物的用途 |
| US10183041B2 (en) | 2017-04-12 | 2019-01-22 | Vector Vitale Ip Llc | Antibacterial composition and its use in treating bacterial infections |
| US10799530B1 (en) | 2019-12-20 | 2020-10-13 | Vector Vitale Ip Llc | Composition and method for the prevention and treatment of obesity |
| US10933091B1 (en) | 2019-12-20 | 2021-03-02 | Vector Vitale Ip Llc | Composition and method for the treatment of type I diabetes |
-
2019
- 2019-10-11 JP JP2022522035A patent/JP7634895B2/ja active Active
- 2019-10-11 US US17/768,190 patent/US11779597B2/en active Active
- 2019-10-11 CA CA3154392A patent/CA3154392A1/en active Pending
- 2019-10-11 WO PCT/US2019/055770 patent/WO2021071499A1/en not_active Ceased
- 2019-10-11 EP EP19795409.2A patent/EP4041214A1/en active Pending
- 2019-10-11 AU AU2019470001A patent/AU2019470001B2/en active Active
-
2023
- 2023-08-28 US US18/238,817 patent/US12036238B2/en active Active
-
2024
- 2024-01-05 JP JP2024000684A patent/JP2024038270A/ja not_active Withdrawn
-
2025
- 2025-07-04 JP JP2025113738A patent/JP2025148408A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023041862A5 (enExample) | ||
| AU2017278245B2 (en) | Composition and method for reducing neutropenia | |
| JP2024015120A5 (enExample) | ||
| JP2025148408A5 (enExample) | ||
| JP2021119189A5 (enExample) | ||
| CN101636145A (zh) | 长期24小时经肠给予左旋多巴/卡比多巴 | |
| HRP20231142T3 (hr) | Kontrolirano oslobađanje 25-hidroksivitamina d | |
| JP2021120379A5 (enExample) | ||
| JP2021169534A5 (enExample) | ||
| JP2021046394A5 (enExample) | ||
| JP2008536940A (ja) | 頭痛の治療のためのトポイラメート組成物 | |
| GB2374008A (en) | Compositions including copper and their uses | |
| JPWO2020257671A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2025506252A (ja) | 鎮痛及び／又は鎮痒機能を有する医薬組成物及びその使用 | |
| Sweet et al. | Methyldopa as an adjunct to levodopa treatment of Parkinson's disease | |
| US20050043274A1 (en) | Pharmaceutical compositions and methods for lowering blood pressure and pulse rate | |
| JP4370169B2 (ja) | 勃起障害の治療のためのアルカノイルｌ−カルニチンの使用 | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| JP2019535830A5 (enExample) | ||
| Brest et al. | Comparative effectiveness of pargyline as an antihypertensive agent | |
| CN111374981A (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 | |
| JP2020528462A (ja) | 片頭痛の予防及び治療に使用するための栄養補助食品 | |
| WO1996011681A1 (en) | Preventive and remedy for diarrhea | |
| JPWO2023089328A5 (enExample) |